Related Experiment Video
Updated: Jul 17, 2026
Screening Ion Channels in Cancer Cells
Published on: June 16, 2023
Lithium ions: a novel treatment for pheochromocytomas and paragangliomas
Ashley Kappes1, Abram Vaccaro, Muthusamy Kunnimalaiyaan
1Department of Surgery, Endocrine Surgery Research Laboratories, Section of Endocrine Surgery, University of Wisconsin, Madison, WI 53792, USA.
Background:
Operative resection is the only curative treatment for patients with pheochromocytomas, paragangliomas, and other catecholamine-producing neoplasms. Activation of glycogen synthase kinase 3beta (GSK3beta) is thought to promote tumor growth and neuroendocrine (NE) peptide secretion in NE neoplasms. Thus, we hypothesized that inhibition of this signaling pathway with lithium chloride (LiCl), a well-known GSK3beta inhibitor, could be a potential therapeutic strategy to control tumor growth and hormone production.
Methods:
Pheochromocytoma PC-12 cells were treated with varying concentrations of LiCl (0 to 30 mM). Levels of active and inactive GSK3beta and NE peptides chromogranin A (CgA) and Mash1 were determined by Western blot. Cellular growth was measured by MTT cell-proliferation assay.
Results:
At baseline, PC-12 cells had increased active GSK3beta signaling. Treatment of PC-12 cells with increasing dosages of LiCl resulted in dose-dependent inhibition of GSK3beta. Importantly, LiCl inhibited pheochromocytoma cellular proliferation significantly. Furthermore, inhibition of GSK3beta by LiCl was associated with marked suppression of CgA and Mash1 levels.
Conclusions:
These data suggest that GSK3beta inhibition may be a novel strategy to treat pheochromocytoma and other catecholamine-producing neoplasms.
Insights
Lithium chloride (LiCl) inhibits glycogen synthase kinase 3beta (GSK3beta) in pheochromocytoma cells, significantly reducing tumor growth and hormone secretion. This suggests GSK3beta inhibition is a promising therapeutic strategy for these neuroendocrine neoplasms.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Pheochromocytomas and paragangliomas are catecholamine-producing neoplasms.
- Glycogen synthase kinase 3beta (GSK3beta) activation promotes tumor growth and peptide secretion.
- Current curative treatment is limited to surgical resection.
Purpose of the Study:
- To investigate the therapeutic potential of GSK3beta inhibition using lithium chloride (LiCl).
- To assess the effect of LiCl on pheochromocytoma cell proliferation and neuroendocrine peptide production.
Main Methods:
- Pheochromocytoma PC-12 cells were treated with varying concentrations of LiCl.
- GSK3beta activity, chromogranin A (CgA), and Mash1 levels were measured by Western blot.
- Cellular proliferation was assessed using MTT assays.
Main Results:
- LiCl demonstrated dose-dependent inhibition of GSK3beta signaling.
- LiCl significantly suppressed pheochromocytoma cell proliferation.
- Inhibition of GSK3beta by LiCl led to reduced levels of CgA and Mash1.
Conclusions:
- GSK3beta inhibition is a potential novel therapeutic strategy for pheochromocytoma.
- LiCl may be effective in controlling tumor growth and hormone production in catecholamine-producing neoplasms.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Mania and Antimanic Drugs: Overview
01:28Drugs Acting on Autonomic Ganglia: Blockers
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: